이벤트

모두 보기
    AACR 2026 Posters

    AACR 2026 Posters

    April 16, 2026
    ~에 공유:

    April 19-22, 2026
    San Diego Convention Center, San Diego, California

    Biocytogen is thrilled to announce our attendance at AACR Annual Meeting 2026 in San Diego! Meet us at Booth #3225 from April 19–22 to explore how our AI-powered RenSuper antibody discovery workstation, fully human therapeutic assets , and cutting-edge preclinical models are pushing the boundaries of drug discovery.

    What's on the Horizon?
    • AI-Powered Antibody Discovery Platform: Experience a live demo of our latest RenSuper AI-powered workstation, designed to streamline antibody discovery.
    • Fully Human Antibody Assets: Explore 24 scientific posters showcasing our latest breakthroughs in fully human mAbs, ADCs, bispecifics, and TCR-based assets.
    • Preclinical Mouse Models: Discover 12 innovative updates highlighting our humanized models and preclinical pharmacology capabilities.
    • Engage & Unwind: Join us for interactive games, exclusive swag, and fresh ideas for your next collaboration!

    Access all of Biocytogen's posters below—download now!

    REQUEST POSTER SCHEDULE A MEETING WITH US

    AACR 2026 Poster Presentations

    RenSuper Biologics - Fully Human Therapeutic Antibody Assets
    Antibody Assets / PlatformPoster Title
    PD1 x VEGFA BsAbA Half-life Extended PD-1×VEGFA Bispecific Antibody Demonstrates Potent Anti-Tumor Activity in Preclinical Models
    DLL3 x CD3 x 4-1BB TriAbBCG024: A Novel DLL3×CD3×4-1BB Trispecific T Cell Engager Enhances T Cell Persistence and Functionality in Preclinical Models
    Nectin-4 x TROP2 BsADCPreclinical Study of BCG039, a Nectin-4×TROP2 Bispecific ADC, in Urothelial Carcinoma and Other Solid Tumor Models
    TM4SF5 ADCBCG015: A First-in-Class Antibody-Drug Conjugate Targeting TM4SF5 for the Treatment of Hepatocellular Carcinoma
    NKG2A mAbBCG010, a Potentially Best-in-Class NKG2A Blocker for Cancer Treatment
    ALPP/ALPG ADCBCG037, a First-in-class Anti-Human ALPP/ALPG Therapeutic ADC That Inhibits Tumor Growth in Pancreatic Cancer and Gastric Cancer PDX Models
    B7-H4 Biparatopic ADCBCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors
    B7-H3 x MUC1 BsADCBCG041: A First-in-Class Bispecific ADC Targeting B7-H3 and the Proximal Membrane Region of MUC1 with Superior Antitumor Activity
    LILRB4 mAbBCG042: A Promising Anti-LILRB4 Antibody with ADCC Enhancement Demonstrates Superior Efficacy in Preclinical Models of Monocytic AML
    RenLite PlatformRenLite® Transgenic Mice Provide a High-quality Platform for Accelerating the Development of Fully Human Bispecific Antibodies or ADCs Worldwide
    MAGE-A1-TCRRenTCR-Derived MAGEA1-Specific TCRs Demonstrated Superior Peptide Sensitivity and Potent Antitumor Activity in vitro and in vivo.
    MAGE-A4 TCRRenTCR-Derived Natural MAGE-A4-Specific TCRs Outperformed Affinity-Enhanced TCRs in Antitumor Efficacy
    MSLN x CDH3 BsADCA Novel MSLN×CDH3 Bispecific Antibody-drug Conjugate (BsADC) Demonstrates Promising Anti-Tumor Efficacy
    FAP × GPC1 BsADCBCG026: FAP × GPC1 Bispecific ADC – A Novel Targeting Approach for Stromal and Tumor Cells in Pancreatic Cancer and Other Solid Tumors
    HER3 × EpCAM BsADCPreclinical Study of BCG044, A Novel Bispecific ADC Targeting EpCAM and HER3 for the Treatment of Colorectal and Other Tumors
    TROP2 x MUC1 BsADCBCG045: A First-in-Class Bispecific ADC Targeting TROP2 and MUC1 Demonstrates Promising Tumor Efficacy and Potentially Reduced Toxicity in Preclinical Studies
    ADAM9 ADCBCG029: An ADAM9-Targeting ADC Featuring a Novel Topoisomerase I Inhibitor Payload Demonstrated Potent Efficacy in PDX Models
    ITGB6 ADCPreclinical Efficacy of BCG018, an ADC Targeting ITGB6 and Incorporating a Topoisomerase I Inhibitor Payload, Was Demonstrated to Be Effective in PDX Models
    CDCP1 ADCBCG046, A CDCP1 ADC That Targets CTF, Has Demonstrated Potent in vitro and in vivo Efficacy
    PTK7 × EGFR BsADCPreclinical Evaluation of BCG017, a Novel Bispecific ADC Targeting PTK7 and EGFR
    5T4 × MUC1 BsADCA Novel Bispecific Antibody-Drug Conjugate, BCG016, That Targets 5T4 and MUC1, Demonstrates Robust Preclinical Antitumor Activity
    RenMice PlatformUnlocking the Full Human Antibody Repertoire: Novel Humanized Antibody Mouse Models with Fully Humanized Lambda Chains and Diversified Genetic Backgrounds
    FOLR1 HcAb-ADCBCG047, A Novel Heavy Chain Antibody-Drug Conjugate Targeting FOLR1, Demonstrates Outstanding Preclinical Antitumor Efficacy
    ITGB6 x B7H3 dual-payload ADCBCG048, a Novel Bispecific Dual-payload ADC Targeting ITGB6 and B7H3, Exhibited Potent Efficacy in Patient-derived Tumor Xenograft Models
    RenNano PlatformRenNano Platform Enables Efficient Discovery of Fully Human VHH Antibodies
    BioMice - Preclinical Humanized Mouse Models
    TargetRelated ModelsPoster Title
    IL23R, IL12RB-hIL23R/hIL12RB1 plus/hIL12RB2 ad miceA Novel Humanized Mouse Model for Evaluating Anti-Human IL23R Drugs
    CD3, EPCAMB-hCD3EDG/hEPCAM miceInnovative Preclinical Mouse Models Support Development of CD3/EPCAM-Targeting T-Cell Engagers
    PD-1, IL2, IL2R, IL15, IL15RB-hPD-1 plus/hIL2/hIL2RA/hIL2RB/hIL2RG/hIL15/hIL15RA miceEmpowering IL-2 Therapy Development: A Novel Humanized Mouse Model with Functional IL-2 and IL-15 Receptors
    HLA-A11.1B-HLA-A11.1 miceHumanized HLA-A11.1 Mice: A Preclinical Platform for Novel Vaccine Evaluation
    HLA-A2.1, HLA-DRB1*1.1B-HLA-A2.1/HLA-DRB1*1.1 miceAdvancing Novel Vaccines: Preclinical Evaluation in HLA-A2.1/HLA-DRB1*1.1 Humanized Mice
    CD8B-hCD8 miceUtilizing a Humanized CD8 Mouse Model for Non-clinical Studies of Cancer Immunotherapy
    CRBNB-hCRBN miceThe B-hCRBN Mice Model Facilitates PROTACs Studies Based on CRBN Ligands
    FcRnB-hFcRn ratFcRn Humanized Rats for Pharmacokinetics Assessment of Antibody Drugs
    FcRnB-hFcRn, rag2 ko miceFcRn Humanized Mice with an Immunodeficient Background Can be Used to Evaluate the Pharmacokinetics of Antibody Drugs while Avoiding Anti-Drug Antibodies
    /B-NDG MHC dKO miceB-NDG MHC I/II DKO mice plus: A Refined Humanized Model for Evaluating T Cell Engager Efficacy and Toxicity
    /B-CDG miceB-CDG mice: A Novel Severe Immunodeficient Model Suitable for Radiotherapeutic and Radiopharmaceutical Evaluation
    /B-NDG hIL15, FcγR KO miceB-NDG hIL15, FcγR KO mice: An Optimized Humanized Model for Evaluating T Cell–Modulating Antibodies